BeCareLink Multiple Sclerosis : Improving Care of MS Patients with enabling technology

by Alan Gilbert

Real time assessment of MS patients using a mobile application using Artificial Intelligence. MS app replace office based test. MS app can more enable regular telemedicine visits to track progress.
New York, NY United States AI in Medicine Connected Health Equity Raise

All Team Company Patients Physicians Hospital Partners Mission Innovation Details Investor Info Due Diligence Docs Supporters Comments Updates

About our project

The problem we solve: More that 1M people in US Total Lifetime Costs of MS is $4.1M per person with MS Average Yearly Healthcare Costs for MS from $30K to $100K

About our solution: Our AI and enabling technology will dramatically change the way that clilnical care is delivered to MS patients in the future. Clinicians that may only see a MS patients once or twice a year, through the use of the mobile app, will be able to set up monthly check-in tele-medicine calls with the patients to check their progress. The AI enabled app completely replicates the gold standard in office test with a home based app solution. The AI enabled app can help a MS patient with improvement in their neuroplasticity. The AI enabled app can predict a patient that is progressing from Mild to Moderate to Severe MS. Clinicians can use this data to prescribe different medication and treatment regimens based on this data.

Progress to date:

$1.5M Raised to date

 

About Our Team

Creator: Alan Gilbert

Location: New York

Bio: Mr. Gilbert is a mission-driven Growth Serial Entrepreneur with an “up through the ranks” experience in the healthcare industry focused on the achievement of systematically improved outcomes and reduced costs across the healthcare continuum. He is involved in initiatives related to the Disruption and Positive Impact of Blockchain, Artificial Intelligence, and Machine Learning in Improved Healthcare Delivery. He is also viewed as a thought leader in the areas of Accountable Care Solutions, Value Based Care and Collaborative Care. He is a frequent contributor to professional online journals as well as a sought after speaker at industry conferences. He possesses a clear understanding of the current healthcare landscape, and has conceived and implemented strategies that resulted in new markets, new clients and increased revenue. Mr. Gilbert benefits from having a well-developed network of long-standing relationships at the executive level, with access and credibility to be viewed as their trusted advisor. Mr. Gilbert has held recent positions as the Vice President, Growth of LumiraDx and the Co-Founder and Chief Growth Officer of TEAM of Care Solutions, LLC. Mr. Gilbert was the Co-Founder of AxSys Health, the U.S. operations of a UK based Collaborative Care Technology Care Company called AxSys Technology. Mr. Gilbert has held management, administrative, technical and operational positions at large integrated academic medical centers and at large consulting firms that focus on the healthcare industry. Specialties: Business Development Strategic Market Planning Market Penetration Vertical Segmentation Client Relationship Management Partnership and Strategic Alliances Strategic Consultative Selling National and International Accounts Vendor Management IT Start-Ups Managing Media Relationships Contract Negotiations

Title: Chief Executive Officer

Advanced Degree(s): MPA

About Our Company

BeCareLink

Location: 590 Madison Avenue
9th floor B2
New York, NY 10022

Founded: 2016

Website: http://becarelink.com/

Product Stage: Prototype/MVP

YTD Sales: Working on it

Employees: 1-2

How We Help Patients

What we are doing with our company is going to revolutionize the way care is delivered to MS patients.

1 - Replication of office test in home setting
2 - Having patient using app will help with patients neuro-plasticity
3 - Provider through telemedicine visits can see patients monthly virtually instead of twice a year in person
4 - Able to enhance office visits with more data on patients
5 - Using AI to predict when a MS patients is moving from Mild to Moderate to Severe MS

How We Help Physicians

What we are doing with our company is going to revolutionize the way care is delivered to MS patients.

1 - Replication of office test in home setting
2 - Having patient using app will help with patients neuro-plasticity
3 - Provider through telemedicine visits can see patients monthly virtually instead of twice a year in person
4 - Able to enhance office visits with more data on patients
5 - Using AI to predict when a MS patients is moving from Mild to Moderate to Severe MS

How We Help Hospitals

What we are doing with our company is going to revolutionize the way care is delivered to MS patients.

1 - Replication of office test in home setting
2 - Having patient using app will help with patients neuro-plasticity
3 - Provider through telemedicine visits can see patients monthly virtually instead of twice a year in person
4 - Able to enhance office visits with more data on patients
5 - Using AI to predict when a MS patients is moving from Mild to Moderate to Severe MS

How We Help Partners

What we are doing with our company is going to revolutionize the way care is delivered to MS patients.

1 - Replication of office test in home setting
2 - Having patient using app will help with patients neuro-plasticity
3 - Provider through telemedicine visits can see patients monthly virtually instead of twice a year in person
4 - Able to enhance office visits with more data on patients
5 - Using AI to predict when a MS patients is moving from Mild to Moderate to Severe MS

Challenge Mission

Affiliation(s)

Timothy Vartanian, MD, PhD - Medical Advisor, Board Member Timothy Vartanian, MD, PhD, is a leading authority on neural regeneration and is the Director of the Judith Jaffe Center at New York-Presbyterian Hospital / Weill Cornell Medical Center. David Putrino, PhD Computational Neuroscience Advisor, Board Member Dave is a physio-therapist with a PhD on neural control and reaching. At Harvard and MIT, David’s positions focused on computational neuroscience. Previously, at NYU, he concentrated on motor control and brain machine interface development research.

Key Milestones Achieved and Planned

- Finalizing MS Clinical Trial with Weill Cornell - Starting MS Longitudinal Randomized Clinical Trial with Academic Medical Center

Our Competitive Advantages

- No other organization has replicated the "Gold Standard testing methodology" completely, while there are multiple MS apps each with a few MS tests. - Other companies have replicated specific tests in the Gold Stand but not the entire Gold Standard - Other competitors dont have the access to the Key Opinion Leaders in MS in the USA that we have

Barriers to Entry

- No other organization has replicated the "Gold Standard testing methodology" completely, while there are multiple MS apps each with a few MS tests. - Other companies have replicated specific tests in the Gold Stand but not the entire Gold Standard - Other competitors dont have the access to the Key Opinion Leaders in MS in the USA that we have

Funding, Partners and Alliances To Date

We have raised 1.5M to date in the initial seed round. We are in the process of raising $2.5M in our final seed round.

Innovation Details

Intellectual Property Summary

I have filed and have been granted a provisional patent.

Clinical Information

Finalizing results to be submitted for Publication from our Multiple Sclerosis Randomized Clinical Trial at Weill Cornell to show that our MS phone based app using AI can replace the test and the scoring of a "Gold Standard" test that is currently administered in a physicians office.

Regulatory Status

We have been advised that we will need to get a Class 1 Medical Device License when we are informing a clinician of data using our AI, Neural Network, Machine Learning algorithms.

How we will use the funds raised

- Funding Senior Management

- Funding Artificial Intelligence / Neural Network / Machine Learning Team

- Funding Development of Next Version of the Mobile Platform

Thank You

What we are doing with our company is going to revolutionize the way care is delivered to MS patients.

1 - Replication of office test in home setting
2 - Having patient using app will help with patients neuro-plasticity
3 - Provider through telemedicine visits can see patients monthly virtually instead of twice a year in person
4 - Able to enhance office visits with more data on patients
5 - Using AI to predict when a MS patients is moving from Mild to Moderate to Severe MS

Investor Info

Market Size

- Getting our MS app to as many of the 400,000 MS patients in the US as possible

- Total Lifetime Costs of MS is $4.1M per person with MS

- Average Yearly Healthcare Costs for MS from $30K to $100K

- Cost of 400,000 MS patients to healthcare system is between $12B and $40B

Projected 3 Year Growth

- Cost of 400,000 MS patients to healthcare system is between $12B and $40B

- Entering into Fee For Value Programs

- 1% of Market costs impacted with cost avoidance is between $120M and $400M

- Taking 10% of avoided costs is revenue of $12M to $40M per year

Revenue Model

- Cost of 400,000 MS patients to healthcare system is between $12B and $40B

- Entering into Fee For Value Programs

- 1% of Market costs impacted with cost avoidance is between $120M and $400M

- Taking 10% of avoided costs is revenue of $12M to $40M per year

- Subsription revenue from in-app avertising within our MS app from Pharmaceutical companies

Competitors

- No other organization has replicated the "Gold Standard testing methodology" completely, while there are multiple MS apps each with a few MS tests.
- Other companies have replicated specific tests in the Gold Stand but not the entire Gold Standard
- Other competitors dont have the access to the Key Opinion Leaders in MS in the USA that we have

Traction

MS Randomized Clinical Trial being finalized and being submitted for publication from Weill Cornell

MS Longitudinal Randomized Clinical Trial starting with an academic medical center

Due Diligence Docs

Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.


Supporters

Comments

    No comments found .

Login to post your comment!
Click here to Login

Updates

    No updates found .

$ 0

pledged of $ 2,500,000 goal

  • 44 Days left

41

Interest
Score

0

Adoption
Score

Alan Gilbert
Chief Executive Officer

Proflle
Contact Me


Rewards All contributions are tax-deductible.